Insider Form 4: ATAI Issues 103k Stock Options to Director Scott Braunstein

Rhea-AI Filing Summary

Form 4 snapshot – ATAI Life Sciences N.V. (NASDAQ: ATAI)

Director Dr. Scott Braunstein reported the grant of 103,000 non-qualified stock options on 26 Jun 2025 at an exercise price of $2.25 per common share. The options expire on 26 Jun 2035 and will vest in full on the earlier of (i) the day prior to the company’s next annual general meeting or (ii) 26 Jun 2026, providing a 12-month maximum vesting horizon. Following the award, Dr. Braunstein now beneficially owns 103,000 derivative securities; no common shares were bought or sold, and no other transactions were reported.

The filing represents routine director compensation under the company’s equity incentive plan. As the grant is at-the-money (current market price ≈ exercise price) and totals roughly <0.1% of shares outstanding, it has minimal dilution impact. Nonetheless, the award aligns the director’s incentives with long-term shareholder value, signalling continued board engagement.

Positive

• Alignment of interests: Option grant ties director compensation to future share price performance, incentivising long-term value creation.

Negative

• Potential dilution: 103 k new options add marginally to share overhang, though impact is immaterial given company’s total shares outstanding.

Insights

Equity Compensation Analyst

TL;DR: Routine option grant; immaterial dilution, modest alignment benefit.

The 103 k option award to Director Braunstein equates to well under 1% of ATAI’s float, posing negligible dilution. Terms are standard—10-year life, 12-month vest. With strike at $2.25 (near recent trading range) the grant is incentivising only if shares appreciate. No open-market buying or selling occurred, so insider sentiment cannot be inferred. Overall, a normal governance event with neutral valuation impact.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Braunstein Scott

(Last) (First) (Middle)

C/O ATAI LIFE SCIENCES N.V.

PROF. J.H. BAVINCKLAAN 7

(Street)

AMSTERDAM P7 1183 AT

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ATAI Life Sciences N.V. [ ATAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$2.25	06/26/2025		A		103,000		(1)	06/26/2035	Common Shares	103,000	$0	103,000	D

Explanation of Responses:

1. The stock option shall vest on the earlier of the day before the ATAI Life Sciences N.V's next annual meeting or June 26, 2026.

	/s/ Ryan Barrett, Attorney-in-fact	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many ATAI stock options were granted to Director Scott Braunstein?

The Form 4 reports 103,000 stock options granted on 26 Jun 2025.

What is the exercise price of the newly issued ATAI options?

The options carry an $2.25 exercise price per common share.

When do the ATAI options vest for Director Braunstein?

They vest on the earlier of one day before the next AGM or 26 Jun 2026.

Did the insider buy or sell any ATAI common shares?

No. The filing shows no acquisition or disposition of common shares—only an option grant.

What is the expiration date of the reported ATAI stock options?

The options expire on 26 Jun 2035, ten years from the grant date.